Meaningful Clinical Impact of ABvac40 in Early‐Stage Alzheimer’s Disease: Results from the AB1601 Phase 2 Study
ABvac40 treatment significantly reduced clinically meaningful cognitive decline, particularly in amyloid-PET positive patients, with the strongest effects in those with the highest antibody levels. These findings highlight ABvac40's potential to influence disease progression in early-stage AD and warrant further studies to explore its impact on brain vessels as potential driver of the observed cognitive benefits.
Authors
- Jesús Canudas
- Ana María Lacosta
- J. Terencio
- Jorge Loscos (ORCID: https://orcid.org/0000-0003-1435-1779)
- María Pascual‐Lucas (ORCID: https://orcid.org/0000-0002-4638-3153)
- María Montañés
- Gerard Piñol‐Ripoll
- Mercè Boada
Institutions
- Universidad de Zaragoza (ES)
- Instituto de Salud Carlos III (ES)
- Universitat Internacional de Catalunya (ES)
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- Hospital Universitari de Santa Maria (ES)
- Hospital Clínic de Barcelona (ES)
- Zaragoza Logistics Center (ES)
- Grifols (Spain) (ES)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_102589
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00